Cyclodextrin-based controlled drug release system.

Because of their bioadaptability and multi-functional characteristics, cyclodextrins (CDs) are capable of alleviating the undesirable properties of drug molecules in various routes of administration through the formation of inclusion complexes. This article outlines the current application of natural and chemically modified CDs in the design of advanced dosage forms. In an oral drug delivery system (DDS), the hydrophilic and ionizable CDs can serve as potent drug carriers in the immediate release- and delayed release-formulations, respectively, while the release rate of water-soluble drugs can be retarded by hydrophobic CDs. Since CDs are able to extend the function of pharmaceutical additives, the combination of molecular encapsulation with other carrier materials will become effective and a valuable tool in the improvement of drug formulation. Moreover, the most desirable attribute for the drug carrier is its ability to deliver a drug to a targeted site; conjugates of a drug with CDs can be a versatile means of constructing a new class of colon-targeting prodrugs. On the basis of this knowledge, the advantages and limitations of CDs in DDS are addressed.

[1]  F. Hirayama,et al.  Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation. , 1992, Chemical & pharmaceutical bulletin.

[2]  T. Nadai,et al.  Sustained release of flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex. , 1997, Biological and Pharmaceutical Bulletin.

[3]  F. Hirayama,et al.  Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics , 1989 .

[4]  I. Habuš,et al.  Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide--amino-beta-cyclodextrins and adamantane conjugates. , 1995, Bioconjugate chemistry.

[5]  I. Miwa,et al.  Kinetic difference between hydrolyses of γ-cyclodextrin by human salivary and pancreatic α-amylases , 1981 .

[6]  K. Uekama,et al.  Combination effects of O-carboxymethyl-O-ethyl-β-cyclodextrin and penetration enhancer HPE-101 on transdermal delivery of prostaglandin E1 in hairless mice , 1993 .

[7]  A. Coleman,et al.  New β-cyclodextrin derivatives possessing biologically active saccharide antennae , 1993 .

[8]  R. Horváth,et al.  A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin , 1993 .

[9]  G. Müller,et al.  Cyclodextrin as Carrier of Peptide Hormones. Conformational and Biological Properties of β-Cyclodextrin/Gastrin Constructs , 1998 .

[10]  J. L. Vila-jato,et al.  Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes , 1996 .

[11]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[12]  T. Loftsson Pharmaceutical applications of β-cyclodextrin , 1999 .

[13]  F. Hirayama,et al.  In‐vitro Evaluation of Biphenylyl Acetic Acid‐β‐Cyclodextrin Conjugates as Colon‐targeting Prodrugs: Drug Release Behaviour in Rat Biological Media , 1996, The Journal of pharmacy and pharmacology.

[14]  Osama A. Soliman,et al.  Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability , 1997 .

[15]  E. Anaissie,et al.  γ-cyclodextrin: Testosterone complex suitable for sublingual administration , 1987 .

[16]  F. Hirayama,et al.  In‐vivo and In‐vitro Correlation for Delayed‐release Behaviour of a Molsidomine/O‐carboxymethyl‐O‐ethyl‐β‐cyclodextrin Complex in Gastric Acidity‐controlled Dogs , 1995, The Journal of pharmacy and pharmacology.

[17]  F. Hirayama,et al.  Release Characteristics of Nifedipine from 2-Hydroxypropyl-β-cyclodextrin Complex during Storage and Its Modification of Hybridizing Polyvinylpyrrolidone K-30 , 1993 .

[18]  F. Hirayama,et al.  Peracylated β‐Cyclodextrins as Novel Sustained‐release Carriers for a Water‐soluble Drug, Molsidomine , 1994, The Journal of pharmacy and pharmacology.

[19]  T Nadai,et al.  Effect of the interaction of drug-beta-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen. , 1989, Chemical & pharmaceutical bulletin.

[20]  K. Hattori,et al.  The specificity of association between concanavalin a and oligosaccharide-branched cyclodextrins with an optical biosensor , 1997 .

[21]  F. Hirayama,et al.  Ethylated beta-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat. , 1987, Journal of pharmaceutical sciences.

[22]  D. Begley,et al.  The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.

[23]  B. Müller,et al.  Cyclodextrin derivatives in pharmaceutics. , 1995, Critical reviews in therapeutic drug carrier systems.

[24]  M. Skiba,et al.  Evaluation of gastrointestinal behaviour in the rat of amphiphilic β-cyclodextrin nanocapsules, loaded with indomethacin , 1995 .

[25]  N. Bodor,et al.  Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-beta-cyclodextrin. , 1988, Drug design and delivery.

[26]  D. Morré,et al.  Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients. , 1997, Biochimica et biophysica acta.

[27]  F. Djedaïni-Pilard,et al.  Synthesis of a new molecular carrier: N-(Leu-enkephalin)yl 6-amido-6-deoxy-cyclomaltoheptaose , 1993 .

[28]  F. Hirayama,et al.  Inhibitory Effect of 2‐Hydroxypropyl‐β‐cyclodextrin on Crystal‐growth of Nifedipine During Storage: Superior Dissolution and Oral Bioavailability Compared with Polyvinylpyrrolidone K‐30 , 1992, The Journal of pharmacy and pharmacology.

[29]  F. Hirayama [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers]. , 1993, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[30]  K. Uekama,et al.  Controlled release of the LHRH agonist buserelin acetate from injectable suspensions containing triacetylated cyclodextrins in an oil vehicle , 1994 .

[31]  Michael Szycher,et al.  High performance biomaterials : a comprehensive guide to medical and pharmaceutical applications , 1992 .

[32]  F. Hirayama,et al.  In vitro and in vivo evaluation of delayed-release behavior of diltiazem from its O-carboxymethyl-O-ethyl-β-cyclodextrin complex , 1993 .

[33]  T. Loftsson,et al.  Design and in vivo testing of 17β-estradiol-HPβCD sublingual tablets , 1996 .

[34]  J. Pitha,et al.  Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. , 1986, Journal of pharmaceutical sciences.

[35]  F. Hirayama,et al.  Release control of theophylline by β-cyclodextrin derivatives: hybridizing effect of hydrophilic, hydrophobic and ionizable β-cyclodextrin complexes , 1991 .

[36]  A. Coleman,et al.  Chemical–enzymatic synthesis and bioactivity of mono-6-[Gal-β-1,4-GlcNAc-β-(1,6′)-hexyl]amido-6-deoxy-cycloheptaamylose , 1995 .

[37]  D. Friend Oral Colon-Specific Drug Delivery , 1992 .

[38]  F. Hirayama,et al.  Utilization of Diethyl-β-Cyclodextin as a Sustained-Release Carrier for Isosorbide Dinitrate , 1988 .

[39]  H. Parrot-Lopez,et al.  Recognition ability and cytotoxicity of some oligosaccharidylsubstituted β-cyclodextrins , 1994, Biology of the Cell.

[40]  D O Thompson,et al.  Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. , 1997, Critical reviews in therapeutic drug carrier systems.

[41]  F. Hirayama,et al.  Design and In‐vitro Evaluation of a Modified‐release Oral Dosage Form of Nifedipine by Hybridization of Hydroxypropyl‐β‐cyclodextrin and Hydroxypropylcellulose , 1993, The Journal of pharmacy and pharmacology.

[42]  K. Uekama,et al.  Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins , 1988 .

[43]  Hans Bundgaard,et al.  Design of prodrugs , 1985 .

[44]  K. Koizumi,et al.  Isolation and characterization of branched cyclodextrins , 1986 .

[45]  B. Müller,et al.  Solubilization of drugs by modified β-cyclodextrins , 1985 .

[46]  V. Stella,et al.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.

[47]  S. Yen,et al.  Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. , 1991, The Journal of clinical endocrinology and metabolism.

[48]  Fumitoshi Hirayama,et al.  Enhanced Bioavailability and Reduced Metabolism of Salbutamol by Perbutanoyl-β-cyclodextrin after Oral Administration in Dogs , 1995 .

[49]  K. Uekama [Pharmaceutical applications of cyclodextrin complexations (author's transl)]. , 1981, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[50]  R. Okamoto,et al.  Synthesis of doxorubicin-cyclodextrin conjugates. , 1994, The Journal of antibiotics.

[51]  N. Bodor,et al.  Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. , 1991, Journal of pharmaceutical sciences.

[52]  A. Larsen,et al.  An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example , 1998 .

[53]  N. Bodor,et al.  The potential use of cyclodextrins in parenteral formulations. , 1989, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[54]  R. Hancock,et al.  Synthesis of bulky beta-lactams for inhibition of cell surface beta-lactamase activity. , 1993, Bioconjugate chemistry.

[55]  K. Himmelstein,et al.  Osmotic flow through controlled porosity films: An approach to delivery of water soluble compounds , 1985 .

[56]  N. Bodor,et al.  Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. , 1988, Journal of pharmaceutical sciences.

[57]  N. Bodor,et al.  Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. , 1993, Journal of pharmaceutical sciences.

[58]  F. Hirayama,et al.  Acid-catalyzed hydrolysis of maltosyl-β-cyclodextrin , 1992 .

[59]  F. Schuit,et al.  Genetic susceptibility for insulin-dependent diabetes mellitus in Caucasians revisited: the importance of diabetes registries in disclosing interactions between HLA-DQ- and insulin gene-linked risk. Belgian Diabetes Registry. , 1995, The Journal of clinical endocrinology and metabolism.

[60]  F. Hirayama,et al.  Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes. , 1990, Journal of pharmaceutical sciences.

[61]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.

[62]  J. Pitha Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. , 1985, Journal of pharmaceutical sciences.

[63]  F. Hirayama,et al.  6A-O-[(4-Biphenylyl)acetyl]-α-, -β-, and -γ-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino] -α-, -β-, and -γ-cyclodextrins : Potential prodrugs for colon-specific delivery , 1997 .

[64]  F. Hirayama,et al.  Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. , 1983, Journal of pharmaceutical sciences.

[65]  Y Horiuchi,et al.  Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin:cellulose derivative combination as a modified-release drug carrier. , 1990, Journal of pharmaceutical sciences.

[66]  F. Hirayama,et al.  Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. , 1998, Journal of pharmaceutical sciences.

[67]  K. Uekama,et al.  Sustained release of buserelin acetate, a luteinizing hormone‐releasing hormone agonist, from an injectable oily preparation utilizing ethylated β‐cyclodextrin , 1989, The Journal of pharmacy and pharmacology.

[68]  K. Uekama,et al.  Cyclodextrins in drug carrier systems. , 1987, Critical reviews in therapeutic drug carrier systems.

[69]  K. Uekama,et al.  Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. , 1997, Journal of pharmaceutical sciences.

[70]  H. Brøndsted,et al.  Current applications of polysaccharides in colon targeting. , 1996, Critical reviews in therapeutic drug carrier systems.

[71]  F. Hirayama,et al.  Crystallization and polymorphic transition behavior of chloramphenicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix , 1997 .

[72]  Jean-Marie Lehn,et al.  Comprehensive Supramolecular Chemistry , 1996 .

[73]  F. Hirayama,et al.  O-carboxymethyl-O-ethylcyclomaltoheptaose as a delayed-release-type drug carrier: improvement of the oral bioavailability of diltiazem in the dog. , 1989, Carbohydrate research.

[74]  N. Bodor,et al.  Redox Drug Delivery Systems for Targeting Drugs to the Brain a , 1987, Annals of the New York Academy of Sciences.

[75]  Valentino J. Stella,et al.  β‐Cyclodextrin Derivatives, SBE4‐β‐CD and HP–β‐CD, Increase the Oral Bioavailability of Cinnarizine in Beagle Dogs , 1995 .